Pre-Conference Seminar Day

Tuesday 19th March 2024

8:15am Check-In & Coffee + Light Breakfast

9:15 am Welcoming Remarks from the IgA Nephropathy Foundation

9:25 am Chair’s Opening Remarks

9:30 am Exploring the Options for Novel Target Candidates Based on Susceptibility Loci Identified Through GWAS

  • Krzysztof Kiryluk Associate Professor of Medicine, Division of Nephrology, Department of Medicine, Columbia University


  • Overview of the genetic architecture of IgA nephropathy
  • Genetic insights into the pathogenic signaling pathways in IgA nephropathy
  • Genetic drivers of IgA production and their relationship to IgA nephropathy
  • Using genetic findings to identify novel drug targets for IgA nephropathy

10:00 am Unravelling the Epidemiological Factors Associated with IgA Nephropathy to Shoot for Targets of Greatest Unmet Need


  • Exploring geographic and environmental variabilities that result in more aggressive phenotypes
  • Understanding how the epidemiology of IgA feeds into target identification and validation
  • Leveraging variation in prevalence, severity and treatment response among different subpopulations of IgA to uncover subtype-specific targets

10:30am Morning Break & Refreshments

11:00 am Panel Discussion | Novel Targets in Development for IgA Nephropathy: Where are the Current Late Phase Trials Heading?


  • From complement to APRIL to ETA: what targets are currently in development and looking most promising?
  • Exploring new treatment possibilities with combinational targeting
  • Exploring the current thinking on IgA pathogenesis to direct priorities for future target development

11:45 am Deciphering the Precise Role of Complement Activation in IgA Nephropathy to Develop Therapeutic Inhibitors


  • Discussing the role of the complement cascade in the pathogenesis of IgA nephropathy
  • Review results of the Phase II trial of RO7434656, an antisense oligonucleotide targeting complement
  • Providing an overview of the Phase III IMAgINATION trial of RO7434656 in patients with IgA nephropathy

12:15 Lunch & Networking

1:15 pm Highlighting the Potential Role of BlyS & APRIL in the Pathogenesis of IgA Nephropathy

  • Kerry Cooper Senior Vice President - Medical Affairs, Vera Therapeutics


  • Discussing the plausible role of both BlyS and APRIL in the pathogenesis of IgA nephropathy
  • Discussing the rationale for combined inhibition of these cytokines in the treatment of IgA nephropathy
  • Reviewing phase 2b data on atacicept in the treatment of IgA nephropathy and the design of the ORIGIN3 study

1:45 pm Rational for Targeting APRIL in IgA Nephropathy


  • Providing an overview of the Sibeprenlimab development program
  • Reviewing the latest data from the phase 2 trial
  • Optimizing trial design for the phase 3 program: The Visionary Trial Design

2:15 pm Comparative Global Analysis of IgAN Patients’ Real-World Experiences: Mapping the Patient Pathway in Diverse Nations


  • Evaluating disease severity, symptom burden, and treatment satisfaction assessments from both IgAN patients and nephrologists
  • Outlining the real-world comparison study methodology and global data gathering process
  • Emphasizing significant findings and the resulting implications derived from the study

2:45 pm Panel Discussion | Evaluating the Evolving Treatment Landscape for IgA Nephropathy: What Happens Next as More & More Therapies Emerge?

  • Jonathan Barratt Professor of Renal Medicine, University of Leicester
  • Kerry Cooper Senior Vice President - Medical Affairs, Vera Therapeutics
  • Krzysztof Kiryluk Associate Professor of Medicine, Division of Nephrology, Department of Medicine, Columbia University
  • Warren Brooks Vice President Medical Affairs, Calliditas Therapeutics
  • Eve Dryer VP Patient Advocacy, Travere Therapeutics, Inc.


  • As more approvals emerge within the IgAN landscape, how will the evolving standard of care make showing efficacy on top of these other therapies harder?
  • It may require multiple therapies with distinct MOAs to optimally treat the patient with IgAN; how can industry best help enhance further knowledge about the efficacy and safety of potential combination therapeutic regimens?
  • Determining which drug is best for which subset of IgAN patients: where do all the current therapies fit into the current standard of care management, and can we use observed differences in responses to match drugs to specific patient populations?
  • Encouraging more effective engagement of patients in treatment and trial decision making 

3:15 pm Chair’s Closing Remarks